Primary Chemoablation of Recurrent Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer With UGN-102: A Single-Arm, Open-Label, Phase 3 Trial (ENVISION)

Authors

Pencho Genov (ORCID: https://orcid.org/0009-0009-3054-5136)
Nikola V. Mihaylov
Alexandre Khuskivadze (ORCID: https://orcid.org/0000-0002-2308-8792)
Michael J. Louie (ORCID: https://orcid.org/0000-0001-5464-8986)
Vasyl Terzi
William C. Huang (ORCID: https://orcid.org/0000-0001-5261-0650)
Sandip M. Prasad
Dimitar Shishkov
Andrew Meads (ORCID: https://orcid.org/0000-0002-0847-1005)
Mark Schoenberg (ORCID: https://orcid.org/0000-0002-7124-0576)
Sunil Raju
Max Kates (ORCID: https://orcid.org/0000-0003-1166-7225)
Brent Burger

Institutions

Albert Einstein College of Medicine (US)
Montefiore Medical Center (US)
Johns Hopkins University (US)
Morristown Medical Center (US)
National Institute of Emergency Medicine "Pirogov" (BG)
Urology Associates (US)
Atlantic Health System (US)

Publication Details

Journal: The Journal of Urology
Published: 2024-10-24
DOI: https://doi.org/10.1097/ju.0000000000004296
Citations: 24
Primary Topic: Bladder and Urothelial Cancer Treatments
Type: article
Field-Weighted Citation Impact: 13.75

Funders

UroGen Pharma

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Primary Chemoablation of Recurrent Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer With UGN-102: A Single-Arm, Open-Label, Phase 3 Trial (ENVISION)

Pencho Genov, Nikola V. Mihaylov, Alexandre Khuskivadze, Michael J. Louie et al.

Oct 24, 2024

24 citations

The Journal of Urology

Bladder and Urothelial Cancer Treatments

13.75

article

Primary Chemoablation of Recurrent Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer With UGN-102: A Single-Arm, Open-Label, Phase 3 Trial (ENVISION)

Pencho Genov, Nikola V. Mihaylov, Alexandre Khuskivadze, Michael J. Louie, Vasyl Terzi, William C. Huang, Sandip M. Prasad, Dimitar Shishkov, Andrew Meads, Mark Schoenberg, Sunil Raju, Max Kates, Brent Burger

October 24, 2024article en

24 citations

Abstract

No abstract available for this paper.

The Journal of UrologyVol. 213(2)

Albert Einstein College of Medicine (US), Montefiore Medical Center (US), Johns Hopkins University (US), Morristown Medical Center (US), National Institute of Emergency Medicine "Pirogov" (BG), Urology Associates (US), Atlantic Health System (US)

UroGen Pharma

Zero hunger

Openalex Percentile: Top 1%

Bladder and Urothelial Cancer Treatments

13.75

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Primary Chemoablation of Recurrent Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer With UGN-102: A Single-Arm, Open-Label, Phase 3 Trial (ENVISION) — Pencho Genov, Nikola V. Mihaylov, et al. · The Journal of Urology (2024) | TGRS Research Map | TGRS